Last reviewed · How we verify
OPC-6535 Tablets (drug)
OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses.
OPC-6535 is a selective antagonist of the P2X7 receptor, an ATP-gated ion channel involved in inflammatory and immune responses. Used for Neuropathic pain, Inflammatory conditions.
At a glance
| Generic name | OPC-6535 Tablets (drug) |
|---|---|
| Sponsor | Otsuka Pharmaceutical Development & Commercialization, Inc. |
| Drug class | P2X7 receptor antagonist |
| Target | P2X7 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
P2X7 receptor antagonism reduces ATP-mediated activation of immune cells and inflammatory pathways. This mechanism is being explored to modulate excessive inflammation and immune activation in various disease states. By blocking P2X7 signaling, the drug aims to reduce pathological inflammation while preserving beneficial immune function.
Approved indications
- Neuropathic pain
- Inflammatory conditions
Common side effects
Key clinical trials
- Pilot Study of Tetomilast in Chronic Obstructive Pulmonary Disease (COPD) Associated With Emphysema (PHASE2)
- FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis (PHASE3)
- FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis (PHASE3)
- CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: